All Articles

The genomics leader posted a 41% revenue surge in 2025 and projects profitability, yet its stock tumbled on what some see as conservative 2026 guidance.

Digi International's new turnkey solution lets MSPs offer enterprise-grade 5G connectivity and recurring revenue without the upfront cost or complexity.

V2X secures a major contract under the MDA's SHIELD program, positioning it to shape the future of America's layered defense with advanced tech.

With a $30M Series A from Five Elms Capital, Trybe is set to revolutionize the spa and leisure industry with AI, challenging legacy systems worldwide.

With a major strategic pivot complete, Gibraltar Industries' leadership will outline its 2026 playbook to investors at a key 'New Ideas' conference.

Interim data suggests LX2020 is well-tolerated and may reduce dangerous arrhythmias by targeting the root cause of PKP2-associated cardiomyopathy.

A new White House executive order and a proposed $1.5T budget are shaking up defense contracting. Here's how agile firms like Volatus are set to win.

Backed by Purolator, a massive network expansion by Williams Pharmalogistics aims to reshape Canada's temperature-controlled medical delivery landscape.

The plant-based food supplier raised its revenue and profit forecast after a strong year-end recovery, sparking investor confidence and signaling operational agility.

TriSalus Life Sciences reports record 53% annual revenue growth, but a closer look reveals a complex financial picture for the oncology innovator.

As the ISS era ends, Mitsubishi Corporation's major investment in Starlab Space secures Japan's future in orbit and heats up the commercial space race.

Adaptive posted a 55% revenue surge in 2025, fueled by its clonoSEQ cancer test. Now, the firm is charting a clear course to company-wide profitability.

With its new thalassemia drug AQVESME launching, Agios aims for blockbuster status while navigating a key safety warning and advancing a broad pipeline.

The pediatric device firm posted 15% growth to $236.1M in 2025, issuing strong 2026 guidance fueled by its specialty bracing and European expansion.

A new clinical trial for AB001, a potent alpha radioligand therapy, offers hope for patients with advanced prostate cancer, including those resistant to current treatments.

As a foundational CFO steps down, XOMA Royalty brings in biotech veteran Jeffrey Trigilio to enhance its dealmaking strategy and expand its royalty portfolio.

A new podcast season peeks inside the minds of the ultra-wealthy as they navigate the complex, often existential, questions that follow massive success.

As FuelCell Energy eyes larger global projects, it hires a legal expert known for scaling power giants, signaling a strategic shift to execution.

A new partnership combines edge computing software and enterprise hardware to ensure retail and logistics operations never stop, even without internet.

With FDA alignment for its rapid postpartum depression therapy and new trials for anxiety, Reunion Neuroscience is pioneering a new era of mental health.